Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 27 Aug 2026Clinical review pending
!
Rapid thoracic, neurological or metabolic complication
Central airway obstruction, SVCO, brain or cord compression, severe SIADH hyponatraemia, ectopic-cortisol infection or thrombosis may accompany an aggressive SCLC presentation.
Action: Stabilise the emergency and obtain rapid tissue and stage through the lung team, correcting sodium at a safe rate and treating airway, venous or neurological compromise immediately while the time-sensitive systemic treatment plan is prepared.
Synopsis
Recognise rapidly disseminating neuroendocrine lung cancer, stage thorax and brain promptly and coordinate time-sensitive chemoradiotherapy, systemic immunochemotherapy and paraneoplastic or supportive care.
SCLC is a high-grade neuroendocrine carcinoma strongly associated with smoking, rapid doubling, early nodal and blood spread and initial chemotherapy and radiation sensitivity.
Obtain adequate tissue quickly but avoid prolonged serial diagnostics; pathology should distinguish SCLC from NSCLC, carcinoid and large-cell neuroendocrine carcinoma.
First-line stage uses contrast CT chest and upper abdomen plus brain MRI, with PET-CT when it will refine a radical limited-stage field or resolve uncertainty.
Key red flags
Stridor, monophonic wheeze, lobar collapse or severe haemoptysis suggests central airway involvement requiring urgent respiratory and interventional assessment.
SVCO presentation
Facial and arm swelling, venous collaterals and positional head pressure from bulky mediastinal disease may require urgent stent or systemic treatment.
Investigation priorities
01
Core or bronchoscopic tissue diagnosisFirst step
Confirm high-grade small-cell neuroendocrine morphology and exclude other lung and metastatic cancers.
02
First-line contrast CT chest and upper abdomenFirst line
Define primary, nodal, pleural, liver and adrenal disease rapidly and identify complications.
Management branches
Stage quicklyAnswer limited versus extensive disease
Pathology confirms or strongly supports SCLC.
Obtain contrast CT and brain MRI promptly, adding PET-CT when it can refine a planned radical field or clarify one decisive site.
Record TNM and whether all known disease fits a tolerable thoracic radiotherapy volume and assess performance, lung, renal, hearing and paraneoplastic complications.
Key medicines
Platinum with etoposideA common 21-day specialist regimen gives cisplatin 75 mg/m² intravenously on day 1 with etoposide 100 mg/m² intravenously on days 1 to 3 for four cycles, with carboplatin substituted by protocol when renal, hearing or fitness factors require.
Atezolizumab with extensive-stage chemotherapyGive atezolizumab 1,200 mg intravenously every 3 weeks with carboplatin and etoposide for four cycles, then continue 1,200 mg every 3 weeks as maintenance under the licensed and current NICE-funded regimen.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.